Mark J Levis

List of Publications by Year in Descending Order

184 papers	12,168 citations	57 h-index	109 g-index
191 ext. papers	14,192 ext. citations	4.8 avg, IF	6.57 L-index

#	Paper	IF	Citations
184	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.. *Blood*, **2022**,	2.2	3
183	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.. *Science Advances*, **2022**, 8, eabl8952	14.3	1
182	The Presence of SETBP1, RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents. *Blood*, **2021**, 138, 1520-1520	2.2	
181	The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. *Cancer Medicine*, **2021**, 10, 797-805	4.8	2
180	Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?. *Best Practice and Research in Clinical Haematology*, **2021**, 34, 101246	4.2	
179	Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. *Blood Advances*, **2021**, 5, 1437-1441	7.8	0
178	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. *Haematologica*, **2021**, 106, 2121-2130	6.6	10
177	Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. *Blood Advances*, **2021**, 5, 2285-2293	7.8	4
176	Arsenic and all- retinoic acid for acute promyelocytic leukemia: yes, it really is as good as it seems. *Haematologica*, **2021**, 106, 3031-3032	6.6	
175	FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 186	21	7
174	Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. *Npj Precision Oncology*, **2021**, 5, 38	9.8	4
173	Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. *Journal of Oncology Pharmacy Practice*, **2021**, 10781552211024727	1.7	1
172	A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors. *Blood Cancer Discovery*, **2021**, 2, 532-547	7	0
171	Potential targeting of FLT3 acute myeloid leukemia. *Haematologica*, **2021**, 106, 671-681	6.6	11
170	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. *Transplantation and Cellular Therapy*, **2021**, 27, 153-162		5
169	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. *Bone Marrow Transplantation*, **2021**, 56, 1180-1189	4.4	22
168	Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2021**, 87, 513-523	3.5	1

167	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. *British Journal of Haematology*, **2021**, 192, 832-842	4.5	4
166	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. *American Journal of Hematology*, **2021**, 96, 735-746	7.1	2
165	Updates on targeted therapies for acute myeloid leukaemia. *British Journal of Haematology*, **2021**,	4.5	10
164	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. *Blood Cancer Discovery*, **2021**, 2, 616-629	7	8
163	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. *Leukemia Research*, **2021**, 110, 106707	2.7	1
162	A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. *Haematologica*, **2021**, 106, 1022-1033	6.6	1
161	FLT3 inhibitors added to induction therapy induce deeper remissions. *Blood*, **2020**, 135, 75-78	2.2	13
160	Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. *Journal of Clinical Pharmacology*, **2020**, 60, 1629-1641	2.9	1
159	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. *Leukemia*, **2020**, 34, 2333-2341	10.7	13
158	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. *Blood Advances*, **2020**, 4, 1711-1721	7.8	12
157	Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. *Clinical Pharmacokinetics*, **2020**, 59, 1273-1290	6.2	15
156	Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. *Oncotarget*, **2020**, 11, 943-955	3.3	10
155	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 300-306	4.7	24
154	A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 226-233.e1	2	7
153	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. *Leukemia*, **2020**, 34, 1563-1576	10.7	7
152	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. *Blood Advances*, **2020**, 4, 5078-5088	7.8	6
151	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. *Haematologica*, **2020**, 105, 161-169	6.6	8
150	Gilteritinib: potent targeting of FLT3 mutations in AML. *Blood Advances*, **2020**, 4, 1178-1191	7.8	35

149	The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. *Blood Advances*, **2020**, 4, 1192-1196	7.8	18
148	Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. *New England Journal of Medicine*, **2019**, 381, 1728-1740	59.2	413
147	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 984-997	21.7	182
146	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. *Journal of Clinical Oncology*, **2019**, 37, 1604-1607	2.2	19
145	Arsenic and old. *Blood*, **2019**, 133, 1392-1393	2.2	
144	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. *Blood Advances*, **2019**, 3, 3052-3061	7.8	8
143	Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. *Blood Advances*, **2019**, 3, 908-916	7.8	25
142	Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. *Oncogene*, **2019**, 38, 687-698	9.2	11
141	Clinical implications of molecular markers in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 20-35	3.8	26
140	Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia*, **2019**, 33, 299-312	10.7	324
139	Midostaurin for patients with acute myeloid leukemia and FLT3 mutations. *Clinical Advances in Hematology and Oncology*, **2019**, 17, 323-325	0.6	1
138	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 2021-2039	1.9	7
137	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. *Cancer*, **2018**, 124, 306-314	6.4	17
136	A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations. *Blood Advances*, **2018**, 2, 825-831	7.8	69
135	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. *American Journal of Hematology*, **2018**, 93, 1136-1141	7.1	54
134	Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML. *Blood*, **2018**, 132, 598-607	2.2	94
133	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. *Blood*, **2018**, 132, 563-563	2.2	23
132	Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study. *Blood*, **2018**, 132, 557-557	2.2	24

131	Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. *Oncotarget*, **2018**, 9, 32885-32899	3.3	12
130	Advances in targeted therapy for acute myeloid leukaemia. *British Journal of Haematology*, **2018**, 180, 484-500	4.5	59
129	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 889-903	21.7	145
128	FLT3 as a marker of minimal residual disease: Time to re-think?. *American Journal of Hematology*, **2017**, 92, 329-330	7.1	4
127	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. *Haematologica*, **2017**, 102, 391-400	6.6	119
126	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. *Blood*, **2017**, 129, 1143-1154	2.2	99
125	The Future of Targeting FLT3 Activation in AML. *Current Hematologic Malignancy Reports*, **2017**, 12, 153-167	4.7	32
124	Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. *Blood*, **2017**, 130, 48-58	2.2	100
123	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. *Lancet Oncology, The*, **2017**, 18, 1061-1075	21.7	305
122	Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. *Hematology/Oncology Clinics of North America*, **2017**, 31, 681-692	3.1	31
121	Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. *Blood*, **2017**, 129, 257-260	2.2	144
120	How I treat FLT3-mutated AML. *Blood*, **2017**, 129, 565-571	2.2	52
119	Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. *Expert Review of Clinical Pharmacology*, **2017**, 10, 1177-1189	3.8	15
118	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. *Cancer Research*, **2017**, 77, 5554-5563	10.1	22
117	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. *Leukemia Research*, **2017**, 61, 25-32	2.7	12
116	FLT3 dancing on the stem cell. *Journal of Experimental Medicine*, **2017**, 214, 1857-1859	16.6	2
115	Midostaurin approved for FLT3-mutated AML. *Blood*, **2017**, 129, 3403-3406	2.2	145
114	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. *Clinical Cancer Research*, **2017**, 23, 697-706	12.9	40

113	FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. *Oncotarget*, **2017**, 8, 10931-10944	3.3	22
112	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. *Blood Advances*, **2017**, 1, 288-292	7.8	58
111	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001. *Blood Advances*, **2017**, 1, 331-340	7.8	42
110	The current therapeutic landscape of FLT3 inhibitors. *Blood Advances*, **2017**, 1, 1944	7.8	1
109	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. *Leukemia*, **2016**, 30, 1916-1920	10.7	59
108	Signaling Adaptation to TKI Treatment Reactivates ERK Signaling in FLT3/ITD Leukemia. *Blood*, **2016**, 128, 33-33	2.2	2
107	Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 4042-4042	2.2	14
106	Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.. *Journal of Clinical Oncology*, **2016**, 34, 7008-7008	2.2	55
105	Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML. *Blood*, **2016**, 128, 5210-5210	2.2	1
104	Carotidynia Heralding the Onset of Acute Leukemia. *American Journal of Medicine*, **2016**, 129, e43-5	2.4	2
103	Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. *Science Translational Medicine*, **2015**, 7, 291ra96	17.5	37
102	FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. *Seminars in Hematology*, **2015**, 52, 193-9	4	32
101	Inhibition of c-Kit by tyrosine kinase inhibitors. *Haematologica*, **2015**, 100, e77-9	6.6	76
100	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. *Journal of Clinical Oncology*, **2015**, 33, 3152-61	2.2	165
99	A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. *Molecular Diagnosis and Therapy*, **2015**, 19, 409-17	4.5	8
98	Targeting FLT3 to treat leukemia. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 37-54	6.4	60
97	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *American Journal of Hematology*, **2015**, 90, 276-81	7.1	114
96	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. *Blood*, **2015**, 125, 3024-31	2.2	212

95	Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphmade (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome. *Blood*, **2015**, 126, 151-151	2.2	4
94	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). *Blood*, **2015**, 126, 319-319	2.2	9
93	Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study. *Blood*, **2015**, 126, 4836-4836	2.2	4
92	Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients: A Feasibility Pilot Study. *Blood*, **2015**, 126, 771-771	2.2	2
91	Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2015**, 33, 7003-7003	2.2	27
90	TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. *Blood*, **2014**, 123, 1525-34	2.2	18
89	Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 2042-8	4.7	178
88	Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1989-95	4.7	25
87	Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. *British Journal of Haematology*, **2014**, 164, 61-72	4.5	72
86	Is targeted therapy feasible in acute myelogenous leukemia?. *Current Hematologic Malignancy Reports*, **2014**, 9, 118-27	4.4	8
85	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. *Leukemia and Lymphoma*, **2014**, 55, 243-55	1.9	70
84	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. *Blood*, **2014**, 123, 94-100	2.2	175
83	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. *Blood*, **2014**, 124, 3817-27	2.2	128
82	FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. *Cancer Research*, **2014**, 74, 5206-17	10.1	18
81	Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. *Future Oncology*, **2014**, 10, 1571-9	3.6	38
80	The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. *Therapeutic Advances in Hematology*, **2014**, 5, 65-77	5.7	128
79	Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. *Blood*, **2014**, 124, 389-389	2.2	69
78	Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2014**, 32, 7027-7027	2.2	15

77	Advances in treating acute myeloid leukemia. *F1000prime Reports*, **2014**, 6, 96		25
76	FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. *International Journal of Hematology*, **2013**, 97, 683-94	2.3	127
75	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. *Hematology American Society of Hematology Education Program*, **2013**, 2013, 220-6	3.1	164
74	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. *Journal of Clinical Oncology*, **2013**, 31, 3681-7	2.2	278
73	FLT3 inhibitor-induced neutrophilic dermatosis. *Blood*, **2013**, 122, 239-42	2.2	35
72	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood*, **2013**, 121, 4655-62	2.2	296
71	Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?. *International Journal of Hematologic Oncology*, **2013**, 2, 9-11	1	1
70	Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 494-494	2.2	31
69	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. *Journal of Clinical Oncology*, **2013**, 31, 7021-7021	2.2	4
68	Efficacy and safety of quizartinib (AC220) in patients age ≥70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2013**, 31, 7023-7023	2.2	3
67	Variations in FLT3 ligand levels during the course of AML treatment.. *Journal of Clinical Oncology*, **2013**, 31, 7026-7026	2.2	1
66	Quizartinib in acute myeloid leukemia. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 586-8	0.6	9
65	A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. *Leukemia Research*, **2012**, 36, 224-31	2.7	45
64	Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. *British Journal of Haematology*, **2012**, 158, 198-207	4.5	6
63	Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. *Blood*, **2012**, 120, 4205-14	2.2	122
62	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. *Nature*, **2012**, 485, 260-3	50.4	525
61	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. *Haematologica*, **2012**, 97, 1736-42	6.6	50
60	Phospho-specific flow: fixating on the target. *Clinical Cancer Research*, **2012**, 18, 1493-5	12.9	1

59	Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations. *Blood*, **2012**, 120, 1341-1341	2.2	3
58	Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. *Blood*, **2012**, 120, 1519-1519	2.2	1
57	Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.. *Blood*, **2012**, 120, 2479-2479	2.2	2
56	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2012**, 120, 48-48	2.2	54
55	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. *Blood*, **2012**, 120, 673-673	2.2	81
54	Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. *Blood*, **2012**, 120, 674-674	2.2	1
53	TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia. *Blood*, **2012**, 120, 866-866	2.2	1
52	Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. *Blood*, **2012**, 120, 1516-1516	2.2	
51	Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1404-9	4.7	107
50	FLT3 inhibitors: a story of the old and the new. *Current Opinion in Hematology*, **2011**, 18, 71-6	3.3	41
49	FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. *Blood*, **2011**, 117, 3286-93	2.2	184
48	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood*, **2011**, 117, 3294-301	2.2	323
47	FLT3/ITD AML and the law of unintended consequences. *Blood*, **2011**, 117, 6987-90	2.2	49
46	The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,. *Blood*, **2011**, 118, 3632-3632	2.2	9
45	The Response of FLT3/ITD AML to FLT3 Inhibition: Apoptosis of Peripheral Blood Blasts and Differentiation of Bone Marrow Blasts. *Blood*, **2011**, 118, 943-943	2.2	
44	Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors. *Blood*, **2011**, 118, 1421-1421	2.2	
43	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 1856-62	2.2	298
42	Will newer tyrosine kinase inhibitors have an impact in AML?. *Best Practice and Research in Clinical Haematology*, **2010**, 23, 489-94	4.2	9

41	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. *Blood*, **2010**, 115, 1425-32	2.2	185
40	Bench to bedside targeting of FLT3 in acute leukemia. *Current Drug Targets*, **2010**, 11, 781-9	3	31
39	Lestaurtinib: a multi-targeted FLT3 inhibitor. *Expert Review of Hematology*, **2009**, 2, 17-26	2.8	12
38	Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. *Blood*, **2009**, 113, 6215-24	2.2	410
37	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. *Blood*, **2009**, 113, 3938-46	2.2	144
36	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). *Blood*, **2009**, 114, 2984-92	2.2	450
35	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. *Blood*, **2009**, 114, 788-788	2.2	11
34	Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk.. *Blood*, **2009**, 114, 789-789	2.2	9
33	Glycosylation and Surface Localization Are Required for FLT3 Activation but Not for FLT3/ITD.. *Blood*, **2009**, 114, 2748-2748	2.2	0
32	Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. *Leukemia and Lymphoma*, **2008**, 49, 852-63	1.9	41
31	Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3. *Blood*, **2008**, 112, 2637-2637	2.2	6
30	Chromosomal defects Detected by SNP-Array-Based Karyotyping Are Independent Predictors of Survival in Acute Myeloid Leukemia (AML). *Blood*, **2008**, 112, 431-431	2.2	1
29	Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. *British Journal of Haematology*, **2007**, 138, 603-15	4.5	27
28	Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. *Blood*, **2007**, 109, 1643-52	2.2	132
27	FLT3: A Prototype Receptor Tyrosine Kinase Target in AML **2007**, 247-261		
26	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. *Blood*, **2006**, 108, 3477-83	2.2	172
25	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. *Blood*, **2006**, 108, 3262-70	2.2	339
24	Prolonged Exposure to FLT3 Inhibitors Leads to Resistance Via Activation of Parallel Signaling Pathways.. *Blood*, **2006**, 108, 1380-1380	2.2	

23	Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. *Blood*, **2005**, 105, 1759-67	2.2	187
22	Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. *Current Opinion in Hematology*, **2005**, 12, 55-61	3.3	11
21	Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. *Blood*, **2005**, 106, 673-80	2.2	115
20	FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. *Blood*, **2005**, 105, 812-20	2.2	164
19	FLT3 tyrosine kinase inhibitors. *International Journal of Hematology*, **2005**, 82, 100-7	2.3	62
18	A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.. *Blood*, **2005**, 106, 403-403	2.2	31
17	Bad Phosphorylation Is Reduced in Response to Inhibition of Constitutively Activated FLT3.. *Blood*, **2005**, 106, 1367-1367	2.2	
16	Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias.. *Blood*, **2005**, 106, 2784-2784	2.2	
15	FLT3 and acute myeloid leukemia: what is the wild type receptor up to?. *Haematologica*, **2005**, 90, 1586	6.6	
14	Kinase inhibitors in leukemia. *Advances in Pharmacology*, **2004**, 51, 1-33	5.7	
13	Small molecule FLT3 tyrosine kinase inhibitors. *Current Pharmaceutical Design*, **2004**, 10, 1183-93	3.3	26
12	FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. *Blood*, **2004**, 103, 267-74	2.2	166
11	Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. *Blood*, **2004**, 103, 1883-90	2.2	132
10	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. *Blood*, **2004**, 103, 3669-76	2.2	542
9	In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. *Blood*, **2004**, 104, 1145-50	2.2	192
8	Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. *Blood*, **2004**, 104, 1841-9	2.2	77
7	Constitutive FLT3 Activation Results in Specific Changes in Gene Expression in Myeloid Leukemic Cells.. *Blood*, **2004**, 104, 1115-1115	2.2	
6	FLT3/ITD Expression Increases Expansion, Survival and Entry into Cell Cycle of Human Hematopoietic Stem Cells.. *Blood*, **2004**, 104, 484-484	2.2	

5	Novel FLT3 tyrosine kinase inhibitors. *Expert Opinion on Investigational Drugs*, **2003**, 12, 1951-62	5.9	26
4	Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. *Journal of Molecular Diagnostics*, **2003**, 5, 96-102	5.1	147
3	A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. *Blood*, **2002**, 99, 3885-91	2.2	401
2	A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. *Blood*, **2001**, 98, 885-7	2.2	174
1	Novel FLT3 tyrosine kinase inhibitors		2